NovaDel issued Canadian patent for oral-spray drug delivery

By Elaine Rigoli

Tampa, Fla., March 22 - NovaDel Pharma, Inc. announced the issuance of a patent by the Canadian Patent Office covering the use of multiple classes of drugs in oral sprays.

Canadian Patent No. 2,252,050 covers a buccal aerosol spray composition for transmucosal administration of a pharmacologically acceptable non-polar solvent propellant selected from the group consisting of alkaloids, antihistamines, steroid hormones, non-steroidal anti-inflammatories, analgesics, benzodiazepines and anti-depressants, according to a company news release.

"This Canadian patent further strengthens NovaDel's intellectual property position in the oral-spray administration of numerous classes of pharmaceuticals. We believe that the application of NovaDel's technology to approved pharmaceutical compounds may provide significant benefits to patients through ease of use as a well as offer a rapid product development and registration strategy to our company and its shareholders," president and chief executive officer Jan Egberts said in the release.

NovaDel's patent portfolio includes 143 issued and pending patent applications worldwide.

NovaDel Pharma Inc. is a Flemington, N.J.-based specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the-counter drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.